LH surge before oocyte retrieval, but immediately after oocyte retrieval allow pituitary LH secretion to be restored so that Gonadotrophin-releasing hormone agonists (GnRHa) are steroid hormones, necessary to support the luteal phase, may routinely used in IVF programmes to prevent an unwanted be stimulated.
LH surge and consequent ovulation. Despite its widespread
More controlled clinical trials are needed to assess the dose use in IVF, a convincing dose recommendation for GnRHa of GnRHa required for optimal conduction of IVF treatment, in IVF does not exist. In our opinion, the lowest possible i.e. absolute suppression of the LH surge, while retaining the dose of GnRHa should be used. Thus, we performed a beneficial effect on IVF outcome (Hughes et al., 1992) .
prospective, randomized, double-blind, placebo-controlled
Determination of the minimal effective dose to suppress the study to determine the minimal daily dose of triptorelin premature LH surge emerges as the first step. Recently, we acetate needed to suppress a premature LH surge during published results from a study about the effects of different IVF treatment in a long protocol. A total of 240 women daily doses of triptorelin acetate on the LH response to a 500 µg (60 in each group) was randomized to either placebo or to GnRH-challenge test before human chorionic gonadotrophin one of three doses of triptorelin, i.e. 15, 50 or 100 µg daily.
(HCG) injection in patients undergoing IVF treatment Ovarian stimulation was performed with two or three (Janssens et al., 1998) . We showed that a daily dose of 15, ampoules of FSH daily. A premature LH surge occurred 50 or 100 µg triptorelin was sufficient to prevent LH release in 23% of placebo-treated patients, but in none of the to such an extent that spontaneous LH surges could no longer triptorelin acetate-treated patients. There were significantly be expected. In the present study, we aimed to assess the more oocytes and embryos in the 50 and 100 µg triptorelin minimal effective daily dose of triptorelin that would prevent groups. There was no dose relationship in rates of either a spontaneous endogenous LH surge during the stimulation implantation, pregnancy, ongoing pregnancy, live birth phase in patients undergoing IVF. or baby take-home. In this study we showed that daily administration of 15 µg triptorelin is sufficient to preventIntroduction years, and had a spontaneous regular cycle between 26 and 32 days. Their infertility was caused by either a tubal, idiopathic or male
The use of gonadotrophin-releasing hormone agonists (GnRHa) factor. The tubal status as cause of infertility was confirmed by a in IVF programmes facilitates the procedure and contributes hysterosalpingography, laparoscopy and/or laparotomy. Women with to improvement of the results (Neveu et al., 1987; Chetkowski another cause of infertility, and those with an elevated serum FSH et al., 1989; Antoine et al., 1990; Hughes et al., 1992 ; Tummon concentration on cycle day 3 (FSH Ͼ10 IU/l) were excluded from et al., 1992) . Suppression of the undesired premature LH the study. Patients who had undergone a previous IVF attempt surge, which has a negative consequence for the success rate without application of a GnRHa, or an IVF treatment according to (Stanger and Yovich et al., 1985; Caspi et al., 1989 ; Abdalla the so-called short protocol with a stimulation phase of Ͻ7 days, et al., 1990) and for the convenience of the patient, is obtained were also excluded.
with GnRHa. Thereby, planning of the IVF treatment, as well
Patients were informed about the risk of a (premature) LH surge, as the timing of oocyte retrieval, is significantly improved and if this were to occur, such patients were offered a free treatment.
The protocol was approved by the Committee on Ethics of Research (Kubik et al., 1990) . BBT ϭ basal body temperature; D1, D2, D3 ϭ days of cycle; E2 ϭ oestradiol; HCG ϭ human chorionic gonadotrophin; LH ϭ luteinizing hormone; P4 ϭ progesterone.
involving Human Subjects of the Vrije Universiteit Medical Center. concentrations of LH, FSH, oestradiol, progesterone and HCG. If an All participants signed an informed consent.
ovarian cyst Ͼ3 cm in diameter was present, a TVS-guided puncture was carried out. Patients started with a basal body temperature (BBT) Treatment protocol on the third day of menses 1. Daily administration of study medication (triptorelin or placebo) was started 7 days following the temperature Assignment The 240 patients were randomized into four groups, each comprising rise, and continued until and including the day of HCG administration 60 patients. Three groups were treated with different doses of (Profasi, 10 000 IU; Serono Benelux, Den Haag, The Netherlands) triptorelin (Decapeptyl; Ferring B.V., Hoofddorp, The Netherlands), preceding oocyte retrieval. Patients were instructed to contact the namely 15, 50 or 100 µg, and one group received a placebo.
IVF department on the first day of bleeding after the start of triptorelin Randomization took place according to a computer-generated random (menses 2). They had to come to the hospital on the second day of list in 12 permutated blocks of 20 patients, each block containing menses 2 (visit 2) to determine serum LH, FSH, oestradiol and HCG five of each dose group. In a sequential fashion, following the list concentrations, and for a TVS to make an inventory of the ovaries. from 1 to 240, the corresponding treatment (having the same sequential If an ovarian cyst Ͼ3 cm diameter was present, study medication number as the subject) was allocated to individual subjects. The was continued and a TVS-guided puncture performed. Ovarian randomization list was kept by Ferring B.V. and not known to stimulation with FSH (Metrodin, 75 IU; Serono Benelux) was started the executors of the study. Randomization took place at the start of on cycle day 3, or 2 days after cyst puncture, with two ampoules the study medication.
i.m. daily when the patient was aged Ͻ35 years, or three ampoules i.m. in patients aged ജ35 years. Patients were monitored routinely Masking from day 5 of the stimulated cycle onwards. This involved blood The placebo injections contained 0.2 ml of a sterile isotonic aqueous sampling for measurement of LH and oestradiol, and TVS to estimate solution in a ready-to-use syringe. The triptorelin injections contained 0.2 ml triptorelin in a sterile isotonic aqueous solution in respectively the number and diameter of the follicles, as well as morning urinary 500 µg/ml, 250 µg/ml and 75 µg/ml concentrations, again in a ready-LH (uLH). This procedure was carried out on alternate days until the to-use syringe; this resulted in the following doses per syringe: leading follicle(s) reached a diameter of 12 mm, after which the 100 µg, 50 µg and 15 µg. The study medication was provided by patients were monitored every day and uLH was checked three times Ferring B.V., uniformly blindly packed and labelled according to the each day (7:00, 15:00 and 23:00 h) (De Lauretis et al., 1994) . Basal randomization list. Sealed and numbered envelopes, each containing uLH was defined as the average of the uLH concentrations determined the dose regimen for one subject, were locked in the pharmacy at the during the follicular phase until the leading follicle reached a diameter site of the investigation. Only in the event of an emergency would of 12 mm. A spontaneous uLH surge was defined as two successive the code be broken for individual subjects, without exposing the increasing uLH concentrations of which the first was at least 2-fold sequence of treatment for other subjects, thus maintaining the integrity higher than the basal uLH level and, in addition, the second elevated of the double-blind procedure.
uLH level needed to be equal to or higher than the first. The time of onset of the uLH surge was defined as the time when the first elevated Protocol uLH concentration was measured (Ransil et al., 1981) . A uLH surge The treatment protocol is illustrated in Figure 1 . All patients came was defined as premature when it had occurred before the criteria for to the hospital on the second day of a period (menses 1/visit 1). A HCG administration were met, these being the presence of at least transvaginal ultrasound (TVS) was performed to exclude the presence of an ovarian cyst, and a blood sample was drawn to determine serum three follicles Ͼ16 mm diameter, of which at least one was ജ18 mm diameter, and a serum oestradiol concentration of ജ1500 pmol/l. Wolfe, 1973) , and for binary data a Cochran-Armitage test (Cochran, 1954; Armitage, 1955) were used. According to the individual ovarian response, the dose of FSH was increased with one or two ampoules, and monitoring was continued ANOVA was applied for comparisons between hormone concentrations, and differences in hormone concentrations. A log until the criteria for HCG injection were met or until a uLH surge occurred. The HCG injection was withheld when oestradiol transformation was applied to the hormone concentrations to achieve homogeneity of variance and normality of residuals. For oestradiol, concentrations reached Ͼ30 000 pmol/l in order to avoid the risk of ovarian hyperstimulation syndrome. Oocyte retrieval was carried out no transformation could be found to satisfy these assumptions, and therefore non-parametric methods were used. To determine the 35 h after HCG injection. In case a spontaneous uLH surge was observed, oocyte retrieval was performed~32-36 h following its first minimal effective dose, comparison between adjacent doses was performed using a published method (Sidak, 1967) . detection (Ramsewak et al., 1990) . Embryo transfer was performed 48 h after oocyte retrieval in cases of one or two embryos present, A Jonckheere-Terpstra test was applied for analysing hormone area under the curve (AUC), follicle, oocyte, embryo and fertilization and at 72 h after oocyte retrieval when more than two embryos were available. This strategy enabled the selection of the most advanced data. The test was also used for analysis of oestradiol values. Adjustments to the significance levels for multiple testing were made and morphologically superior embryos for transfer. Remaining embryos were cryopreserved in liquid nitrogen at -196°C. Luteal (Sidak, 1967) . The Cochran-Armitage test was applied for comparisons in support was generally accomplished by vaginal administration of 200 mg micronized progesterone (Progestan; Organon, Oss, The occurrence of urinary LH surge and of premature urinary LH surge, for rates of (ongoing) pregnancy, live-birth and baby take-home. To Netherlands) three times daily. Patients who preferred injections rather than vaginal tablets received 1500 IU HCG (Pregnyl ® ; Organon) determine the minimal effective dose, comparisons between the adjacent doses were performed using a continuity corrected chii.m. on days 2, 4, 6, 8 and 10 after oocyte retrieval, but only when the oestradiol concentration on the day of the HCG injection was square test or, when the incidence was Ͻ5 in all dose groups, a Fisher's exact test. Ͻ8000 IU/l.
A result was considered statistically significant if the P-value was Ͻ 0.05. The minimal effective dose was that where LH suppression Ultrasound occurred in 95% of the patients. All ultrasound examinations were performed transvaginally by either
Intention to treat analysis (ITT, of all patients who were included of two of the authors (R.J. and J.B.) using Toshiba ultrasound in the study) and protocol population analysis (PP, of evaluable equipment (Tosbee, Model SSA-240A, probe 5 MHz model PVEpatients) were performed. The results from the analysis of the protocol 582V). To determine the diameter of the follicle, the mean of population were identical to those from the ITT population. Therefore, measurements in two perpendicular directions was taken. Ultrasound only the results of the ITT population are presented in detail. guidance was used in all cases for follicle aspiration and oocyte recovery.
Results

Serum assays
Baseline characteristics
Blood samples for LH, FSH, oestradiol and progesterone were collected in heparinized tubes and centrifuged at 1800 g for 10 min.
The baseline characteristics, i.e. actual age, age of menarche, To determine FSH and LH, a commercially available immunometric number of smokers, cycle length, duration of infertility and assay kit (Amerlite, Amersham, Bucks, UK) was used. For measuring body mass index were comparable between the four groups.
concentrations of oestradiol and progesterone, a commercially availFurthermore, no significant differences were found in type of able competitive immunoassay (Amerlite) was used. Intra-and interinfertility or hormone (LH, FSH, oestradiol, progesterone) assay coefficients of variation were 6% and 9% for FSH, 5% and concentrations. Values are shown in Table I. 10% for LH, 9% and 11% for oestradiol, and 11% and 17% for progesterone.
Participant flow and follow-up
Among the 240 patients, there were 11 withdrawals divided Urinary LH assay over the four dose groups: one withdrew from the placebo Urinary LH was measured by immunometric assay (Amerlite) for group, four from the 15 µg group, four from the 50 µg group, LH in serum, after the following modification. An aliquot of each urine sample was diluted with four aliquots of zero calibrator in order and two from the 100 µg group. Three patients quit triptorelin to compose a serum matrix. Values were calculated allowing for the treatment after a few days, for different reasons: one patient dilution. The intra-and inter-assay coefficient of variation was in the 15 µg group stopped because her husband became ill, between 6% and 10% respectively. and two patients in the 50 µg group conceived spontaneously while using triptorelin. Two other patients had a withdrawal failing to conform to the protocol due to relational problems µ0 ജ µ15 ജ µ50 ജ µ100).
(placebo group, n ϭ 1), violation of the protocol by using the For continuous normally distributed data, a linear contrast of dose standard triptorelin of 100 µg instead of her study medication was tested in a one-way analysis of variance (ANOVA); for ordinal (ordered categorical) data, a Jonckheere-Terpstra test (Hollander and (15 µg group, n ϭ 1) and drug interruption for 48 h (which Values are mean Ϯ SD.
ITT ϭ intention to treat, i.e. analysis on all subjects who entered the study.
was more than the 6 h permitted in the protocol) (50 µg group, ment at visit 2 (P Ͻ 0.001) (Table II) , as well as for the difference between visit 1 and visit 2 (P ϭ 0.009) (Table II) . n ϭ 1), while one patient in the 100 µg group withdrew her consent. Two other patients (one each in the 15 µg and 50 µg Desensitization/FSH stimulation phase groups) were ultimately not considered eligible for the study because they did not respond exactly to our inclusion criteria.
The interval between the start of FSH in combination with A total of 229 patients was recorded as completing the study study medication until HCG injection or spontaneous LH surge, according to protocol, and considered to be evaluable per was defined as the desensitization/FSH stimulation phase. protocol for efficacy.
Luteinizing hormone Fourteen (23%) of the placebo-treated patients had an LH Desensitization phase surge, of whom 10 (17%) were premature, i.e. before the The interval between initiation of study medication and start criteria for HCG were met. None of the triptorelin-treated of FSH stimulation was defined as the desensitization phase.
patients had an LH surge. Statistical analysis for linear trend The time lapse between the start of the triptorelin acetate and with dose was highly significant (P Ͻ 0.001) (Figure 2 ). the onset of subsequent menses was shorter in the placebo Adjacent comparison for the occurrence of both LH surges group than in the active medication groups (P Ͻ 0.001) and premature LH surges showed significance between placebo (Table II) . and 15 µg (P Ͻ 0.05). In order to characterize the endocrine pituitary and ovarian LH secretion during combined agonist and FSH treatment response to triptorelin or placebo, differences were measured was estimated by AUC per stimulation day (LH-AUC/day). between serum concentrations of LH and oestradiol on day There was strong decrease upon increasing doses (P Ͻ 0.001) 2 of menses 1 (visit 1), and immediately prior to FSH (Figure 3) . Adjacent comparison showed a significant differstimulation, i.e. day 2 of menses 2 (visit 2). Mean LH ence in dose means between 15 and 50 µg, but not between concentrations ranged from 3.6 to 4.1 IU/l in all dose groups placebo and 15 µg, nor between 50 and 100 µg. at visit 1. After desensitization (at visit 2), mean LH concentra-
Duration of FSH stimulation and number of FSH ampoules tions were lower compared with the values at visit 1 in all
The mean duration of FSH stimulation (days) increased with dose groups, except for the placebo group. Linear trend tests the dose of triptorelin (P Ͻ 0.001) (Table III) . Adjacent on log transformed values showed a highly significant dose comparison showed a significant difference between the response (P Ͻ 0.001) for both the value at visit 2 and the placebo and 15 µg groups. The mean daily dose of FSH (mean difference between values at visit 1 and visit 2. For both number of ampoules/day) was similar in all dose groups; parameters, adjacent comparisons showed a statistically signitherefore, the total number of FSH ampoules used showed a ficant difference between the effect of placebo and 15 µg clear increase with higher dose of triptorelin (P Ͻ 0.001) triptorelin, but not between 15 and 50 µg, or between 50 and (Table III) . 100 µg (Table II) .
At visit 1 the mean oestradiol concentrations ranged from Oestradiol and progesterone During FSH stimulation there was a statistically significant 106 to 119 pmol/l. There was a highly significant dosedependent decline of oestradiol after placebo/triptorelin treatdifference on dose-response effect for oestradiol secretion (P Ͻ 0.05) ( Table IV) . The dose-response for log-transformed progesterone data significant difference between the 15 and 50 µg groups, but was statistically significant on the day of HCG injection not between the placebo and 15 µg groups, nor between the (P Ͻ 0.001), with highest progesterone values in the placebo 50 and 100 µg groups. The mean numbers of oocytes were group. Adjacent comparisons showed a statistically significant higher in the 50 µg and 100 µg groups (11 and 12 respectively) difference between the placebo and 15 µg groups (Table IV) . compared with the placebo and 15 µg groups (seven and nine Number of follicles respectively). The number of follicles of Ͼ12 mm diameter on the day of For the number of embryos per study entrance, adjacent HCG/LH surge was analysed. There was a statistically signicomparisons showed significant differences between the ficant dose-response relationship for the number of follicles placebo and 15 µg groups and between the 15 and 50 µg Ͼ12 mm diameter (P ϭ 0.032) (Table IV) .
groups, but not between the 50 and 100 µg groups. The mean number of embryos was higher in the 50 and 100 µg groups IVF outcome There was a significant dose dependence in the number of (seven in each group) compared with the placebo and 15 µg groups (three and five respectively). oocytes retrieved (P ϭ 0.001) and the number of embryos obtained (P ϭ 0.001) ( Table V) . For the number of oocytes
The number of embryos transferred was comparable between the four groups (Table V) . However, in the placebo group, per study entrance (ITT), adjacent comparisons showed a 22% of the patients did not reach an embryo transfer, this Discussion being highly significant compared with the 8% who did
We describe here the results of the first placebo-controlled, not reach transfer in the other three dose groups (χ 2 test, double-blind study to determine the lowest effective dose for P ϭ 0.0039).
the GnRH agonist triptorelin to prevent an LH surge during The fertilization rate (number of fertilized oocytes/number IVF. This is more than a decade after the introduction and of retrieved oocytes, as %) increased significantly with the wide application of this treatment strategy. From the outset, dose of triptorelin used (P ϭ 0.029), but adjacent comparison empirical doses were chosen that warranted full desensitization of doses did not show any significant differences (Table V) .
of the pituitary, and thus its inability to secrete LH. These The implantation rate (total number of pregnancies with one doses originated from oncological treatment schedules for or more gestational sacs/embryo transfer, as %) was not disseminated prostate cancer (Tolis et al., 1982) . In these significantly different, and there was no evidence of any doseregimens the advised dose for triptorelin-which was the drug response relationship (Table V) .
of choice in our study-was estimated to be at least 100 µg There was no significant linear trend with dose for pregnancy daily. Several authors suggested that partial desensitization of rate (number of positive pregnancy tests/number of ITT the pituitary would be feasible (Broekmans et al., 1996; patients, as %) , either for ongoing pregnancy rate (number of Scheele et al., 1996) and applicable in IVF (Ron-El et al., pregnancies with positive fetal heart beat action at 11 weeks 1992), and that dose reduction should be possible. We have after oocyte retrieval/number of ITT patients, as %), or for shown in an earlier study that graded desensitization could be live birth rate (number of babies born alive/number of ITT achieved under IVF conditions (Janssens et al., 1998) ; morepatients, as %) or baby take-home rate (number of babies over, it appeared that a daily dose of 50 µg triptorelin taken home after the IVF treatment/number of ITT patients, creates a state of pituitary desensitization comparable with the 'standard' dose of 100 µg, and this endocrine finding was as %) (Table V) . confirmed in the current study. The power of the current study direct ovarian influence of the agonist on the ovary (Hsueh and Jones, 1981) , though the strong dose dependency does not now also allows us to conclude that, from a clinical point of view, no differences exist between these two doses.
rule out indirect effects. One explanation would be that a longer duration of stimulation with FSH with higher daily From the present study it clearly follows that a lower daily dose of triptorelin (50 µg or 15 µg) than is currently used is doses of agonist enables more follicles to enter the stage of FSH-dependent growth. Another explanation might be the capable of preventing a LH surge, but with a lower grade of pituitary desensitization, as shown by the higher LH secretion greater suppression of endogenous LH than FSH by the higher doses of GnRHa, resulting in an increase in the FSH/LH in the stimulatory phase. In terms of implantation rate, pregnancy rate and baby take-home rate, the results of the ratio during the follicular phase (Stone et al., 1989) . Both explanations are in line with the theory that multiple follicle higher dose groups appear to be better, although the differences were not significant. Therefore, on the basis of these observagrowth is achieved by extending the time when FSH is above threshold ('widening the gate'), as proposed previously (Baird, tions we conclude that a reduction of the daily dose of triptorelin by 50% is possible, without negatively affecting the 1987). In our study there was indeed a dose-dependent increase in the number of follicles Ͼ12 mm diameter, and a larger success rate.
In our study, the number of patients who did not receive number of oocytes with higher agonist doses. With regard to this point, it is remarkable that a dose-finding study with a embryo transfer was reduced by 50% when GnRHa was given, compared with placebo. This is in line with other observations GnRH-antagonist, in contrast, suggests less follicle growth and lower oocyte yield with higher doses (The Ganirelix Dose- (Kubik et al., 1990; Polson et al., 1991) , and again substantiates the usefulness of agonists in IVF.
Finding Study Group, 1998) . We confirm an increase in fertilization rate with the use of Our study also shows the dose dependency of several other remarkable features on the use of GnRHa in IVF. Various a GnRH agonist (Neveu et al., 1987; Antoine et al., 1990) , and substantiate its dose dependency. This indicates the apparent studies have reported the recovery of more oocytes in GnRHtreated IVF cycles than in non-GnRH cycles (Neveu et al., improvement of oocyte quality which, currently, is believed to be the beneficial result of the lower LH concentrations 1987; Testart et al., 1989; Maroulis et al., 1991; Ron-El et al., 1991) , and the improvement of ovarian responsiveness with during the stimulation phase found with the increasing dose of agonist. High LH concentrations during follicular development microdoses of GnRHa during ovulation induction for IVF in poor responders (Feldberg et al., 1994; Scott and Novot, 1994;  may influence oocyte quality, fertilization rate and embryo quality (Stanger and Yovich, 1985; Howles et al., 1987) . Olivennes et al., 1996) . However, we are the first to report a dose effect of the GnRHa on the number of oocytes and So far, a higher fertilization rate, no difference in number and quality of embryos (data not shown), and no difference embryos in normal responders. This may be related to possible
